These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24729718)

  • 1. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.
    Hedari CP; Khinkarly RW; Dbaibo GS
    Infect Drug Resist; 2014; 7():85-99. PubMed ID: 24729718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.
    Ghanem S; Hassan S; Saad R; Dbaibo GS
    Expert Opin Biol Ther; 2013 Aug; 13(8):1197-205. PubMed ID: 23815506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
    Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix
    Dhillon S; Pace D
    Drugs; 2017 Nov; 77(17):1881-1896. PubMed ID: 29094312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
    Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
    Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
    Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
    Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
    Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MD; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Wittermann C; Bleckmann G; Fischbach T; Kolhe D; van der Wielen M; Baine Y
    Pediatr Infect Dis J; 2017 Apr; 36(4):e98-e107. PubMed ID: 28002359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
    Díez-Domingo J; Simkó R; Icardi G; Chong CP; Zocchetti C; Syrkina O; Bchir S; Bertrand-Gerentes I
    Infect Dis Ther; 2024 Aug; 13(8):1835-1859. PubMed ID: 38955966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
    Bona G; Castiglia P; Zoppi G; de Martino M; Tasciotti A; D'Agostino D; Han L; Smolenov I
    Vaccine; 2016 Jun; 34(29):3363-70. PubMed ID: 27181507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents.
    Serra LC; York LJ; Balmer P; Webber C
    J Adolesc Health; 2018 Sep; 63(3):269-279. PubMed ID: 30236996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
    Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
    Marshall GS; Pelton SI; Robertson CA; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
    Croxtall JD; Dhillon S
    Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.
    Jonker EFF; van Ravenhorst MB; Berbers GAM; Visser LG
    Vaccine; 2018 Jun; 36(26):3727-3732. PubMed ID: 29778515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
    Serra L; Webber C; Burman C; Bueti P; Gorruso M; Mather S
    Vaccine; 2022 Nov; 40(49):7014-7021. PubMed ID: 36283896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.
    Martinón-Torres F; Serra L; Safadi MAP
    Expert Rev Vaccines; 2020 Apr; 19(4):313-325. PubMed ID: 32250710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.